Neon Therapeutics (NTGN) Reaches New 12-Month Low at $5.51
Neon Therapeutics Inc (NASDAQ:NTGN) reached a new 52-week low during trading on Thursday . The company traded as low as $5.51 and last traded at $5.86, with a volume of 6649 shares trading hands. The stock had previously closed at $6.15.
A number of research firms have commented on NTGN. Zacks Investment Research upgraded Neon Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a research report on Friday, November 16th. LADENBURG THALM/SH SH began coverage on Neon Therapeutics in a research report on Monday, October 1st. They issued a “buy” rating and a $20.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, Neon Therapeutics presently has a consensus rating of “Buy” and an average target price of $18.08.
Neon Therapeutics (NASDAQ:NTGN) last released its quarterly earnings results on Monday, November 12th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.12. As a group, sell-side analysts anticipate that Neon Therapeutics Inc will post -5.17 earnings per share for the current fiscal year.
About Neon Therapeutics (NASDAQ:NTGN)
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Featured Article: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.